1246960-15-5

Basic information

• Product Name: (S)-1-chloro-3-(2,4,5-trifluorophenyl)propan-2-ol
• Synonyms: (S)-1-chloro-3-(2,4,5-trifluorophenyl)propan-2-ol
• CAS NO: 1246960-15-5
• Molecular Weight: 224.61
• Mol File: 1246960-15-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 272.3±35.0 °C(Predicted)
• Density: 1.398±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (S)-1-chloro-3-(2,4,5-trifluorophenyl)propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-chloro-3-(2,4,5-trifluorophenyl)propan-2-ol(1246960-15-5)
• EPA Substance Registry System: (S)-1-chloro-3-(2,4,5-trifluorophenyl)propan-2-ol(1246960-15-5)

Safety Data

• Hazardous Substances Data: 1246960-15-5(Hazardous Substances Data)

Usage

General Description

(S)-1-chloro-3-(2,4,5-trifluorophenyl)propan-2-ol, also known as atomoxetine, is a chemical compound with the formula C9H10ClF3O. It is a selective norepinephrine reuptake inhibitor and is commonly used as a treatment for attention deficit hyperactivity disorder (ADHD). Atomoxetine works by increasing the levels of norepinephrine in the brain, which helps to improve focus and reduce impulsivity and hyperactivity in individuals with ADHD. The compound is a white to off-white solid that is slightly soluble in water and is typically administered orally in the form of capsules or a liquid solution. Atomoxetine is considered to be non-stimulant and non-addictive, making it a popular alternative to other ADHD medications. However, it is also associated with potential side effects such as insomnia, decreased appetite, and increased heart rate.

Upstream product

• 327-52-6 1-bromo-2,4,5-trifluorobenzene 
• 67843-74-7 (S)-epichlorohydrin 
• 502462-00-2 (2,4,5-trifluorophenyl)-magnesium bromide 

Downstream Products

• 1283096-74-1 (S)-3-hydroxy-4-(2,4,5-trifluorophenyl)butanenitrile 
• 868071-17-4 3(S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutanoic acid 
• 1283096-72-9 (2S)-2-(2,4,5-trifluorobenzyl)-oxirane 
• 486460-32-6 sitagliptin 
• 1253055-98-9 (R)-3-azido-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one 
• 1293293-73-8 (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid 
• 1293293-72-7 (2S)-1-(2-azido-4-pentenyl)-2,4,5-trifluorobenzene 
• 1293293-71-6 (2R)-1-(2,4,5-trifluorophenyl)-4-pentene-2-ol 
• 486460-00-8 (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoic acid 
• 1246960-25-7 (R)-3-(((benzyloxy)carbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoic acid 
• 1246960-17-7 (R)-t-butyl 2-(2,4,5-trifluorobenzyl)aziridine-1-carboxylate 
• 1246960-18-8 (R)-benzyl 2-(2,4,5-trifluorobenzyl)aziridine-1-carboxylate 
• 1246960-20-2 (R)-2-((2,4,5-trifluorobenzyl)aziridine-1-yl)phenylmethanone 
• 1246960-21-3 (R)-(9H-fluorene-9-yl)methyl 2-(2,4,5-trifluorobenzyl)aziridine-1-carboxylate 

Relevant articles and documents

Intermediate of Sitagliptin and synthesis method of intermediate

The invention provides an intermediate of Sitagliptin and a synthesis method of the intermediate. The intermediate is the compound of formula (I), and the synthesis method comprises enabling the compound of the formula (3) to react with cyan-containing salt to obtain the compound of the formula (2), and hydrolyzing the compound of the formula (2) by use of alkali. The synthesis method is short in reaction path, the reaction reagent is cheap, and the expensive reagent in the traditional process is avoided to use, the production cost can be effectively lowered, the synthesis time is shortened, and the industrial production is facilitated. The intermediate of the Sitagliptin manufactured by use of the synthesis method is large in yield, high in purity, and in favor of the preparation of high-quality Sitagliptin.

METHOD FOR PREPARING SITAGLIPTIN AND AMINE SALT INTERMEDIATES USED THEREIN

The present invention relates to a method for preparing sitagliptin by using an amine salt of (3R)-3-azido-4-(2,4,5-trifluorophenyl)-butyric acid (formula (V)) in a high yield and purity, and amine salt intermediates used therein.

METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN

Disclosed are a novel, simple and low-cost method for preparing sitagliptin, as DPP-IV (dipeptidyl peptidase IV) inhibitor, which is useful in treating type 2 diabetes mellitus and key intermediates used in said preparation of sitagliptin.